ONCE DAILY REGIMEN OF DIDANOSINE, TENOFOVIR AND EFAVIRENZ

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。该研究的主要目的是(1)确定艾滋病毒感染在体内不同部位(包括血液、精液、阴道分泌物和脊液)如何发展，以及人体对新感染的病毒有何反应；(2)了解对新感染的艾滋病毒感染者来说，每天一次联合抗逆转录病毒治疗的安全性和耐受性如何，并了解这种治疗方法在多大程度上限制了对免疫系统的损害；(3)确定新感染者中耐药病毒的频率及其对治疗反应的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purposes of the study are (1) to determine how HIV infection develops at various sites in the body (including blood, semen, vaginal secretions and spinal fluid) and how the body responds to new infection, (2) to find out how safe and well tolerated once a day dosing of combination antiretroviral treatment is for new HIV infected persons, and to see how well this treatment limits the damage to teh immune system, and (3) to determine the frequency of resistant viruses in newly infected persons and how and if they affect response to treatment.